VNRX (VolitionRX) LT-Debt-to-Total-Asset : 0.50 (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is VolitionRX LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. VolitionRX's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.50.

VolitionRX's long-term debt to total assets ratio increased from Dec. 2023 (0.16) to Dec. 2024 (0.50). It may suggest that VolitionRX is progressively becoming more dependent on debt to grow their business.

VolitionRX LT-Debt-to-Total-Asset Historical Data

The historical data trend for VolitionRX's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX LT-Debt-to-Total-Asset Chart

VolitionRX Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.11

0.20

0.16

0.50

VolitionRX Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.21	0.35	0.37	0.50

VolitionRX LT-Debt-to-Total-Asset Calculation

VolitionRX's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	4.692	/	9.4
	=	0.50

VolitionRX's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	4.692	/	9.4
	=	0.50

VolitionRX (AMEX:VNRX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

VolitionRX LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of VolitionRX's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

VolitionRX Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VolitionRX Ltd (AMEX:VNRX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.volition.com

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Executives

Guy Archibald Innes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef	officer: Chief Scientific Officer	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds	director, officer: PRESIDENT AND CEO	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Eight Corp Ltd	10 percent owner	C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert	director, officer: SECRETARY	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes	director	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall	director	1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Michel Gaetan	other: Manager Belgian Volition SPRL	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway	other: CEO-Singapore Volition	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer	officer: GC - Volition Diagnostics	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor	officer: Group Chief Marketing Officer	1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md	officer: Chief Medical Officer	1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014